Gandeeva Therapeutics Announces Appointment of Dr. Brenda G. Cooperstone to its Board of Directors

Gandeeva Therapeutics, Inc., a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the appointment of Brenda G. Cooperstone, MD, as an independent member of its Board of Directors. Dr. Cooperstone is a pharmaceutical executive with more than 20 years of experience in drug development. She most recently served as the Chief Development Officer, Rare Diseases and the Pennsylvania Site Head for Pfizer Inc.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005821/en/

Dr. Brenda G. Cooperstone (Photo: Business Wire)

"We are excited to welcome Dr. Cooperstone to Gandeeva's Board of Directors," said Sriram Subramaniam, Ph.D., Founder and CEO of Gandeeva Therapeutics. "Dr. Cooperstone brings significant clinical development, regulatory, and portfolio strategy experience to our team, and we are thrilled to work with her as we advance our pipeline of innovative medicines to the clinic."